Vertex reported Q2 adjusted EPS of $4.73 and revenue of $3.33B, with sales beating Wall Street expectations. Sector: Biotechnology Key Highlights 💰 Revenue: $3.33B vs. $3.22B est. 💊 Adjusted EPS: $4.73 vs. $4.75 est. 📈 Strong product sales supported growth 🧬 Continues expanding biotech portfolio 🚀 Revenue exceeded analyst estimates Why It Matters Strong revenue growth reinforces Vertex's leadership in biotech despite a slight EPS miss.